CGTLive®’s Weekly Rewind – January 24, 2025
Review top news and interview highlights from the week ending January 24, 2025.
CGTLive®’s Weekly Rewind
Welcome to CGTLive®’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
1. All of Atara Biotherapeutics’ T-Cell Immunotherapy Trials Placed on Clinical Hold by the FDA
The holds are related to a GMP compliance issue at a third-party manufacturing facility.
2. David Porter, MD, on Progress With Cross-Disciplinary Collaboration in Cell Therapy for Autoimmune Disease
The director of cell therapy and transplant at Penn Medicine also summed up his main message regarding the current state of the field in general.
3. First Patient Dosed in Phase 3 Trial for Intellia Therapeutics’ Hereditary Angioedema Gene Editing Therapy NTLA-2002
The company stated it expects to submit a BLA to the FDA next year.
4. Sarah Larson, MD, on Evaluating Lyell’s CAR-T IMPT-314 in LBCL
The medical director of the Immune Effector Cell Therapy Program at UCLA discussed initial data from a phase 1/2 trial.
5. Solid Biosciences’ INSPIRE DUCHENNE Study Puts DMD Gene Therapy SGT-003 to the Test
CGTLive took a closer look at the first-in-human clinical trial for the next-generation gene therapy.
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Jeffrey Chamberlain, PhD, on the Import of Early Intervention in DMD
July 10th 2025The McCaw Endowed Chair of Muscular Dystrophy at University of Washington, discussed how comprehensive care for DMD patients involves early diagnosis, steroid treatment, consideration of mutation-specific therapies, and more.
